Vor Biopharma (VOR) Return on Capital Employed (2021 - 2026)
Vor Biopharma's (VOR) quarterly Return on Capital Employed came in at 79.58% in Q1 2026, up 3210.0% year-on-year from 2.4% in Q1 2025, and up 36.83% on a QoQ basis from 125.98% in Q4 2025.
Vor Biopharma (VOR) Return on Capital Employed (2021 - 2026) Analysis & Trends
Vor Biopharma (VOR) has 6 years of Return on Capital Employed data on file, last reported at 79.58% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 3210.0% year-over-year to 79.58% in Q1 2026; TTM through Mar 2026 was 79.58%, a 3210.0% increase from a year earlier, with the FY2025 full-year figure at 133.52%, down 5374.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 79.58%, up from 125.98% in the prior quarter.
- Over the last five years, Return on Capital Employed for VOR reached as high as 35.45% in Q1 2022 and fell as low as 372.73% in Q2 2025.
- Historically, Return on Capital Employed has averaged 96.21% across 5 years, with a median of 75.54% in 2024.
- Across the five-year window, Return on Capital Employed sank 28391 bps in 2025 and soared 3210 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 38.96% in 2022, then slumped by 66 bps to 64.63% in 2023, then slumped by 69 bps to 109.34% in 2024, then declined by 15 bps to 125.98% in 2025, then jumped by 37 bps to 79.58% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 79.58% in Q1 2026, 125.98% in Q4 2025, and 213.41% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Vor Biopharma | 187.37 Mn | 187.37 Mn | - | -79.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.58% |
| Dec 31, 2025 | -125.98% |
| Sep 30, 2025 | -213.41% |
| Jun 30, 2025 | -372.73% |
| Mar 31, 2025 | -111.68% |
| Dec 31, 2024 | -109.34% |
| Sep 30, 2024 | -103.10% |
| Jun 30, 2024 | -88.82% |
| Mar 31, 2024 | -75.54% |
| Dec 31, 2023 | -64.63% |
| Sep 30, 2023 | -55.34% |
| Jun 30, 2023 | -44.30% |
| Mar 31, 2023 | -36.63% |
| Dec 31, 2022 | -38.96% |
| Sep 30, 2022 | -42.56% |
| Jun 30, 2022 | -37.53% |
| Mar 31, 2022 | -35.45% |
| Dec 31, 2021 | -28.70% |
| Sep 30, 2021 | -25.76% |
| Jun 30, 2021 | -21.60% |